Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
|
30365932 |
2019 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We studied thirteen single nucleotide polymorphisms (SNPs) located in SFRP3 (rs7775), CTNNB1 (β-catenin) [rs4135385, rs13072632], APC (rs454886, rs459552), LRP6 (rs2075241, rs2284396), DKK4 (rs3763511), DKK3 (rs6485350), TCF4 (rs12255372) and AXIN2 (rs3923086, rs3923087, rs4791171) in patients with colorectal cancer (n = 122) and controls (n = 110).
|
31485167 |
2019 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
hTERT may promote CRC by recruiting β-catenin/TCF-4 complex to transactivate CCL2 expression, which is a novel crosstalk mechanism likely involved in the pathogenesis of CRC.
|
30970512 |
2019 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We then focused on transcription factor 4 (TCF4) as it is downregulated in CRC and associated with increased stemness in tumors.
|
31540772 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings first demonstrate that miR-452-GSK3β-LEF1/TCF4 positive feedback loop induce CRC proliferation and migration.
|
30253791 |
2018 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In our study, firstly by analyzing a ChIP-seq dataset against TCF4, the core transcription factor for initiation of Wnt signaling in colorectal cancer (CRC) cells, we screened out several tumor-suppressive miRNAs potentially regulated by Wnt signaling.
|
28921929 |
2018 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer.
|
28051067 |
2017 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dickkopf-related protein 4 (DKK4) is a target of the β-catenin/transcription factor 4 complex in colorectal cancer.
|
28356933 |
2017 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we quantify promoter methylation of ITF2 and APC by MethyLight in two case-case studies nested in population-based CRC cohorts from the Ontario Familial Colorectal Cancer Registry (n = 330) and the Newfoundland Familial Colorectal Cancer Registry (n = 102) comparing MSI status groups.
|
26884349 |
2016 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
OVOL2 bound T-cell factor (TCF)4 and β-catenin, facilitating recruitment of histone deacetylase 1 to the TCF4-β-catenin complex; this inhibited expression of epithelial-to-mesenchymal transition-related genes regulated by WNT, such as SLUG, in CRC cell lines.
|
26619963 |
2016 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TCF4 Is a Molecular Target of Resveratrol in the Prevention of Colorectal Cancer.
|
25961950 |
2015 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Human colorectal carcinoma tissue arrays were used to associate levels of ITF2 expression and clinical outcomes.
|
24846398 |
2014 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In human tumours, GATA6 competes with β-catenin/TCF4 for binding to a distal regulatory region of the BMP4 locus that has been linked to increased susceptibility to development of CRC.
|
24952462 |
2014 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Firstly, we investigated biochemical interaction by inhibiting STAT3 and β-catenin (through gene knock-down and dominant-negative TCF4 expression) in nine CRC cell lines.
|
25348333 |
2014 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that Tcf-4 is an attractive potential therapeutic target for colorectal cancer therapy.
|
23029137 |
2012 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In our previous work, we showed that the colorectal cancer (CRC) risk variant rs6983267 at 8q24 resides within a TCF4 binding site at the MYC-335 enhancer, with the risk allele G having a stronger binding capacity and Wnt responsiveness.
|
22429595 |
2012 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Silencing of TCF4 caused a significant sensitization of CRC cells to clinically relevant doses of X-rays.
|
21983179 |
2011 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upregulation of MT1-MMP and LAMC2 by β-catenin/TCF4 has been linked to invasiveness in CRCs, and we show here that both proteins are activated by ZEB1 coexpressing with it in primary colorectal tumors with mutated APC.
|
22080605 |
2011 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The overexpression of some proproliferative and antiapoptotic genes, such as survivin, telomerase catalytic subunit (hTERT), integrin-linked kinase (ILK), and regulatory factors c-MYB and Tcf-4, has been implicated in the development and progression of several human malignancies including CRC.
|
20027603 |
2010 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings illustrate an effective therapeutic principle in CRC based on a combination targeting strategy that includes the ITF2 oncogene, which represents a novel therapeutic target.
|
20823162 |
2010 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The element drove expression of a reporter gene in a pattern that is consistent with regulation by the key CRC pathway Wnt. rs6983267 affects a binding site for the Wnt-regulated transcription factor TCF4, with the risk allele G showing stronger binding in vitro and in vivo.
|
19561604 |
2009 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations of BAX (G8) and TCF-4 (A9), which are common in MSI-positive colorectal cancer, occurred at rates of 22.7 and 0%, respectively, which suggests that the MSI target gene may differ between endometrial and colorectal cancers.
|
19787250 |
2009 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The activity of the Bcl-w promoter was increased or decreased, respectively, by overexpression of beta-catenin or dominant negative TCF4. beta-catenin is activated in the majority of CRC and these results suggest that BCL-W may function as a downstream effector of inappropriate WNT/beta-catenin signalling.
|
19124064 |
2009 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The ITF-2 gene is located in the chromosomal region 18q21; allelic loss of this locus occurs in 70% of colorectal cancers.
|
19394332 |
2009 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report that DKK4 is frequently down-regulated in colorectal cancer cell lines with deregulated beta-catenin/Tcf-4 and in primary colorectal cancers.
|
19059704 |
2009 |